Sigrid Raises $5 Million to Accelerate U.S. Growth and Broaden SiPore® Health Platform

New updates have been reported about Sigrid.

Sigrid, a Swedish medtech and consumer health company focused on metabolic health, has secured a new USD 5 million financing round, lifting its total capital raised to approximately USD 27 million. The funding, backed by both existing and new international investors, will primarily support the company’s expansion in the U.S. market, where its flagship non-systemic dietary supplement, Glucose Stabiliser, has delivered more than 3x revenue growth over the past year across direct-to-consumer channels and a growing physician network. Management positions this performance as evidence of strong product-market fit and recurring demand in the rapidly expanding metabolic health segment, driven by rising global focus on blood sugar control and sustainable weight management.

The fresh capital also underpins Sigrid’s push to convert its SiPore® technology into a broader, multi-vertical platform. The company has submitted a technical file for CE-mark approval in the EU for an over-the-counter medical device designed to support weight reduction and metabolic health in adults with excess weight and elevated blood sugar, intended for use within structured lifestyle programs. In parallel, Sigrid is developing SiPore®-based solutions beyond metabolic health, targeting future applications in oral care, veterinary health, and food technology, and is in active partnership discussions with major consumer health, nutrition, and pharmaceutical companies for licensing and distribution. With more than 15 years of research behind its non-systemic, gut-localized mechanism of action, Sigrid aims to position SiPore® as a scalable platform for global brands seeking clinically validated, low-risk interventions in multiple consumer and health-related categories.